A5008842761- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Metabolism, Diabetes, and Cancer
- Diabetes Management and Research
- Cardiovascular Function and Risk Factors
- Pharmacology and Obesity Treatment
- Diet and metabolism studies
- Heart Failure Treatment and Management
- Peptidase Inhibition and Analysis
- Cardiac Imaging and Diagnostics
- Chronic Kidney Disease and Diabetes
- Receptor Mechanisms and Signaling
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Blood Pressure and Hypertension Studies
- Inflammatory mediators and NSAID effects
- Adipokines, Inflammation, and Metabolic Diseases
- Lipoproteins and Cardiovascular Health
- Coronary Interventions and Diagnostics
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Heart Rate Variability and Autonomic Control
- Neuropeptides and Animal Physiology
- Diet, Metabolism, and Disease
- Neurological Disorders and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Diabetes and associated disorders
Nestlé (Switzerland)
2020-2025
Boehringer Ingelheim (Norway)
2014-2024
Vestre Viken Hospital Trust
2012-2023
Boehringer Ingelheim (Germany)
2012-2020
Boehringer Ingelheim (Canada)
2013-2020
Bærum Sykehus
2003-2019
University of Toronto
2013-2017
Lunenfeld-Tanenbaum Research Institute
2017
St. Michael's Hospital
2016-2017
Mount Sinai Hospital
2017
The effects of empagliflozin, an inhibitor sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality patients with type 2 diabetes at high risk are not known.We randomly assigned receive 10 mg or 25 empagliflozin placebo once daily. primary composite outcome was death from causes, nonfatal myocardial infarction, stroke, as analyzed the pooled group versus group. key secondary plus hospitalization for unstable angina.A total 7020 were treated...
Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced major events in patients with type diabetes at high for We wanted to determine long-term effects analysis that was prespecified component secondary microvascular outcome trial.We randomly assigned estimated glomerular filtration rate least 30 ml per minute 1.73 m(2) body-surface area receive either empagliflozin (at...
Background— The primary objective of this mechanistic open-label, stratified clinical trial was to determine the effect 8 weeks’ sodium glucose cotransporter 2 inhibition with empagliflozin 25 mg QD on renal hyperfiltration in subjects type 1 diabetes mellitus (T1D). Methods and Results— Inulin (glomerular filtration rate; GFR) paraaminohippurate (effective plasma flow) clearances were measured individuals based having (T1D-H, GFR ≥ 135 mL/min/1.73m , n=27) or normal (T1D-N, 90–134 n=13) at...
Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but included limited numbers patients high risk and chronic kidney disease.To evaluate the effect linagliptin, a selective DPP-4 inhibitor, on outcomes in type at events.Randomized, placebo-controlled, multicenter noninferiority trial conducted from August 2013 to 2016 605 clinic sites 27 countries among adults diabetes, hemoglobin A1c...
In the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial involving 7,020 patients with type diabetes and established cardiovascular (CV) disease, empagliflozin given addition to standard of care reduced risk CV death by 38% versus placebo (hazard ratio [HR] 0.62 [95% CI 0.49, 0.77]). This exploratory mediation analysis assesses extent which treatment group differences covariates during contributed reduction...
Type 2 diabetes is associated with increased cardiovascular risk. In placebo-controlled safety trials, the dipeptidyl peptidase-4 inhibitor linagliptin demonstrated noninferiority, but it has not been tested against an active comparator.This trial assessed outcomes of vs glimepiride (sulfonylurea) in patients relatively early type and risk factors for or established atherosclerotic disease.Randomized, double-blind, active-controlled, noninferiority trial, participant screening from November...
To determine the effects of empagliflozin on blood pressure (BP) and markers arterial stiffness vascular resistance in patients with type 2 diabetes mellitus (T2DM).We conducted a post hoc analysis data from phase III trial T2DM hypertension receiving 12 weeks' four trials 24 (cohort 1, n = 823; cohort 2, 2477). BP was measured using 24-h monitoring 1) or seated office measurements 2).Empagliflozin reduced systolic (SBP) diastolic both cohorts (p < 0.001 vs placebo), without increasing heart...
Individuals with type 1 diabetes mellitus are at high risk for the development of hypertension, contributing to cardiovascular complications. Hyperglycaemia-mediated neurohormonal activation increases arterial stiffness, and is an important factor hypertension. Since sodium glucose cotransport-2 (SGLT2) inhibitor empagliflozin lowers blood pressure HbA1c in mellitus, we hypothesized that this agent would also reduce stiffness markers sympathetic nervous system activity. Blood pressure, heart...
In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) patients with type diabetes mellitus and atherosclerotic cardiovascular disease, comparison placebo, empagliflozin reduced risks of 3-point major adverse events (3-point MACE), all-cause death, hospitalization for heart failure. We investigated whether these effects varied across spectrum baseline risk.
Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF) hospitalizations in patients with type 2 diabetes (T2D) established CV disease (CVD) EMPA-REG OUTCOME® trial. We investigated whether benefit empagliflozin was observed across spectrum HF risk.Seven thousand twenty T2D (HbA1c 7-10% eGFR > 30 mL/min/1.73 m2) were treated 10 or 25 mg, placebo once daily followed for median 3.1 years. In without at baseline (89.9%), we derived 5-year incident using 9-variable...
Evidence concerning the importance of glucose lowering in prevention cardiovascular (CV) outcomes remains controversial. Given multi-faceted pathogenesis atherosclerosis diabetes, it is likely that any intervention to mitigate this risk must address CV factors beyond glycemia alone. The SGLT-2 inhibitor empagliflozin improves control, body weight and blood pressure when used as monotherapy or add-on other antihyperglycemic agents patients with type 2 diabetes. aim ongoing EMPA-REG OUTCOME™...
CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (NCT01243424) is an ongoing, randomized trial subjects with early type diabetes and increased cardiovascular risk or established complications that will determine the long-term impact linagliptin versus sulphonylurea glimepiride. Eligible patients were sulphonylurea-naïve HbA 1c 6.5%–8.5% previously exposed to (in monotherapy a combination regimen <5 years) 6.5%–7.5%. Primary outcome time first occurrence...
Individuals with type 2 diabetes mellitus are at increased risk for heart failure (HF), particularly those coexisting atherosclerotic cardiovascular disease and/or kidney disease. Some but not all dipeptidyl peptidase-4 inhibitors have been associated HF risk. We performed secondary analyses of and related outcomes the inhibitor linagliptin versus placebo in CARMELINA (The Cardiovascular Renal Microvascular Outcome Study With Linagliptin), a trial that enrolled participants...
Fetuin A has been associated with insulin resistance and the metabolic syndrome. We therefore explored role of fetuin in nonalcoholic fatty liver disease (NAFLD).Cross-sectional intervention studies.We included 111 subjects histologically proven NAFLD whom 44 participated a randomized, controlled trial metformin. One hundred thirty-one healthy 13 undergoing hepatic surgery for metastatic cancer served as controls. Main outcome variables were circulating levels according to presence NAFLD,...
To investigate the pharmacodynamics, efficacy and safety of empagliflozin as adjunct to insulin in patients with type 1 diabetes.A total 75 glycated haemoglobin (HbA1c) concentrations ≥7.5 ≤10.5% (≥58 ≤91 mmol/mol) were randomized receive once-daily 2.5 mg, 10 25 or placebo for 28 days. Insulin dose was be kept stable possible 7 days then adjusted, at investigator's discretion, achieve optimum glycaemic control. The primary exploratory endpoint change from baseline 24-h urinary glucose...
Aims: To determine the effects of empagliflozin on adiposity indices among patients with type 2 diabetes mellitus. Methods: Changes in weight, waist circumference, estimated total body fat, index central obesity and visceral were assessed using analysis covariance testing treatment by strata for age, sex baseline circumference mellitus randomized to blinded versus placebo clinical trials 12 weeks (cohort 1) or 24 2) duration. Results: This study comprised 3300 1, N = 823; cohort 2, 2477)....
In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), empagliflozin added to standard of care patients with type diabetes mellitus and high cardiovascular risk reduced 3-point major adverse events, driven by a reduction mortality, no significant difference between placebo myocardial infarction or stroke. modified intent-to-treat analysis, hazard ratio for stroke was 1.18 (95% confidence interval, 0.89-1.56; P=0.26). We further...
In the EMPA-REG BP trial, empagliflozin 10 mg and 25 once daily reduced glycohemoglobin, blood pressure (BP), weight versus placebo in patients with type 2 diabetes mellitus hypertension. Patients received (n=271), (n=276), or (n=276) for 12 weeks (n=full analysis set). This present investigated changes from baseline to week mean 24-hour systolic (SBP) diastolic (DBP) receiving 0, 1, ≥2 antihypertensive medications receiving/not diuretics angiotensin-converting enzyme inhibitors/angiotensin...
The cardiovascular (CV) safety of linagliptin was evaluated in subjects with type 2 diabetes (T2DM). Pre-specified patient-level pooled analysis all available double-blind, randomized, controlled trials, ≥12 weeks' duration (19 9459 subjects) versus placebo/active treatment. Primary end point: composite prospectively adjudicated CV death, non-fatal myocardial infarction, stroke, and hospitalization for unstable angina (4P-MACE). Hospitalization congestive heart failure (CHF) also evaluated;...